As of April 2015, 21 states have chosen not to expand Medicaid eligibility under the Affordable Care Act. All but one of those states have also chosen to rely on federally facilitated marketplaces.
As of April 2015, 21 states have chosen not to expand Medicaid eligibility under the Affordable Care Act. All but one of those states have also chosen to rely on federally facilitated marketplaces.
If the Supreme Court finds for the plaintiff in King v. Burwell, the combined effect of not expanding Medicaid and losing federal support for marketplace coverage for the low-income population would be dramatic for the 20 states affected by both decisions.
In total, 9.8 million people would be uninsured who would have otherwise been insured. Assuming that marketplace financial assistance is not replaced and assuming those states do not choose to expand Medicaid, the total loss in federal spending from 2016 to 2025 would be $721 billion.
Read the full brief at the Urban Institute: http://urbn.is/1Jhwe0X
Neurologists Share Tips for Securing Patient Access to Gene Therapies
March 19th 2025Tenacious efforts at every level, from the individual clinician to the hospital to the state to Congress, will be needed to make sure patients can access life-saving gene therapies for neuromuscular diseases.
Read More
Bustling Gene Therapy Pipeline for Neuromuscular Diseases Brings Thorny Questions to the Clinic
March 18th 2025The rapid development of gene therapy options for treating neuromuscular diseases has created new therapeutic options but also logistical hurdles and a need for complex discussions between clinicians and families.
Read More